Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study

What this Trial Is About

Researchers are studying adults aged 65 and older with cancer who are planned to receive chemotherapy and have a pre-frail or frail status based on the Electronic Frailty Index (eFI). The study aims to better understand the needs of these patients by measuring their resilience and tailoring care plans to their individual health status during chemotherapy. This prospective single-arm intervention trial seeks to improve supportive care for this population. Participants will be enrolled before starting chemotherapy and undergo a baseline assessment. They will receive feedback on their frailty status and be offered referrals for supportive care interventions designed to reduce chemotherapy toxicity. Over 12 weeks, participants will complete weekly symptom reports through electronic surveys and phone calls with a research nurse. Follow-up assessments will occur at 12 weeks, and some participants and providers will be invited to interviews to provide feedback on the intervention, including challenges and helpful factors. During the study, participants will be monitored for symptom changes and healthcare use such as hospital admissions and emergency visits. Researchers will track recruitment, retention, and completion rates of symptom assessments. The total participation lasts 12 weeks from chemotherapy initiation, with data collected through surveys, phone calls, medical records, and interviews to better tailor supportive care for older adults undergoing chemotherapy.

Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway